Ligand id: 7422

Name: dacomitinib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 79.38
Molecular weight 469.17
XLogP 3.97
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
In September 2018 the FDA granted approval for dacomitinib's use as a first-line treatment for patients with metastatic NSCLC with EGFR mutations (exon 19 deletion or exon 21 L858R substitution). EMA approval for this indication was granted in April 2019. Visit ClinicalTrials.gov to view currently registered drug trials involving this compound.
Mechanism Of Action and Pharmacodynamic Effects
Dacomitinib is an irreversible inhibitor of HERs (EGFR, and ERBBs).